Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.49 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151872 | 0.89 | DPP4 (0.54) | DPP4F2RL3ALOX5APFEN1 | |
| SCHEMBL5151871 | 0.89 | DPP4 (0.54) | DPP4F2RL3ALOX5APFEN1 | |
| SCHEMBL31615587 | 0.85 | DPP4 (0.45) | DPP4ALOX5APFEN1NPC1 | |
| SCHEMBL5152041 | 0.84 | ALOX5AP (0.46) | DPP4F2RL3ALOX5APFEN1GPR119 | |
| SCHEMBL14569576 | 0.84 | DPP4 (0.46) | DPP4ALOX5APNPC1 | |
| SCHEMBL5149970 | 0.84 | ALOX5AP (0.48) | ALOX5APFEN1GPR119NPC1CHEK2 | |
| SCHEMBL5149980 | 0.84 | ALOX5AP (0.48) | ALOX5APFEN1GPR119NPC1CHEK2 | |
| SCHEMBL6289529 | 0.81 | F2RL3 (0.49) | F2RL3ALOX5APFEN1GPR119 | |
| SCHEMBL14557756 | 0.81 | DPP4 (0.47) | DPP4 | |
| SCHEMBL5150218 | 0.81 | ALOX5AP (0.50) | F2RL3ALOX5APFEN1GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | DPP4 288/4885F2RL3 100/4885ALOX5AP 246/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | DPP4 366/4885F2RL3 94/4885ALOX5AP 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.